Summary of Significant Accounting Policies - Additional Information (Detail)
$ / shares in Units, Unit in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 26, 2013
Sep. 30, 2013
USD ($)
Oct. 31, 2009
shares
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Customer
Segment
Unit
$ / shares
shares
Dec. 31, 2014
USD ($)
$ / shares
shares
Dec. 31, 2013
USD ($)
$ / shares
shares
Schedule Of Significant Accounting Policies [Line Items]                  
Stockholders reverse stock split             1-for-8    
Stockholders reverse stock split, ratio 0.125                
Stock split effective date Aug. 09, 2013                
Number of operating segments | Segment             2    
Foreign currency re-measurement losses             $ 70,000 $ 33,000 $ 47,000
Common stock, shares issued | shares     1,362,500       12,215,000 12,186,000  
Warrants to purchase common stock, in shares | shares     681,275            
Derivative liability, fair value, gross liability                 400,000
Derivative gain (loss) fair value of stock warrants             $ 0 $ 0  
Expense (income) recognized on adjustment of fair value of stock warrant liability       $ 1,000 $ 70,000 $ 309,000 0 (379,000) (794,000)
Reserves for excess and obsolete inventory             300,000 36,000  
Net of allowance for doubtful accounts             7,538,000 5,289,000  
Unbilled accounts receivable             $ 1,900,000 $ 700,000  
Number of major customers | Customer             2    
Number of reporting unit | Customer             2    
Goodwill impaired             $ 0    
Number of months before product expiration during which customer can return product               3 months  
Number of months after product expiration during which customer can return product               12 months  
Share based compensation             $ 1,800,000 $ 600,000 500,000
Weighted average period to recognize unamortized share-based compensation cost related to non-vested stock options             5 years 5 months 16 days    
Cash received from option exercised             $ 82,000 33,000 11,000
Company options granted to employees, in shares | shares             630,000    
Share based compensation expense allocation             $ 1,750,000 607,000 475,000
Tax benefit recognized               $ 0 $ 0
Antidilutive securities excluded from computation of earnings per share | shares             1,087,308 1,692,180 1,599,551
Acquisition-related expense             $ 0 $ 0 $ 1,623,000
Research and Development [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Share based compensation expense allocation             $ 1,126,000 2,000  
Allowance for Sales Returns [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Sales returns reserve               2,000  
Current Period Sales [Member] | Allowance for Sales Returns [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Sales returns reserve               $ 0  
Milestone 1 [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Discount volume levels | Unit             10    
Milestone 2 [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Discount volume levels | Unit             20    
Milestone 3 [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Discount volume levels | Unit             30    
Merck KGaA [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Revenue recognition, recorded revenue cost plus percentage             20.00%    
Additional license and supply agreement renewals term             5 years    
License and supply agreement expiration date             May 19, 2020    
Minimum [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Finite-lived intangible asset, useful life             3 years    
Minimum [Member] | Merck KGaA [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Revenue recognition, recorded revenue cost plus percentage             20.00%    
Maximum [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Finite-lived intangible asset, useful life             7 years    
Employees [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Weighted average grant date fair values of options granted | $ / shares             $ 4.38 $ 4.27 $ 3.52
Non Employees [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Company options granted to employees, in shares | shares             243,000    
Share based compensation expense allocation             $ 1,100,000    
Weighted average grant date fair values of options granted | $ / shares             $ 4.52 $ 0.00 $ 0.00
Non Employees [Member] | Research and Development [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Weighted average period to recognize unamortized share-based compensation cost related to non-vested stock options             1 year 3 months    
Company options granted to employees, in shares | shares             240,000    
Consultants [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Share based compensation expense allocation               $ 0 $ 0
Employee Stock Option [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Unamortized share-based compensation cost related to non-vested stock options not yet recognized             $ 2,600,000    
Weighted average period to recognize unamortized share-based compensation cost related to non-vested stock options             2 years 7 months 6 days    
Company options granted to employees, in shares | shares             387,000 312,000 88,749
Other Stock Options [Member] | Non Employees [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Weighted average period to recognize unamortized share-based compensation cost related to non-vested stock options             3 years 9 months    
Company options granted to employees, in shares | shares             3,000    
Juniper Pharma Services [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Assumed obligation under grant arrangement by the entity   $ 3,900,000              
Juniper Pharma Services [Member] | Regional Growth Fund [Member]                  
Schedule Of Significant Accounting Policies [Line Items]                  
Assumed obligation under grant arrangement by the entity             $ 2,500,000    
Deferred revenue             $ 1,500,000 $ 2,100,000